NF2, now officially called NF2-related schwannomatosis, is a genetic condition that causes noncancerous tumors to grow along nerves in the brain and spinal cord. Its hallmark is the development of tumors on both hearing and balance nerves, which affects roughly 88% of people with the condition. Symptoms typically appear between ages 18 and 24, though they can start as early as birth or as late as age 70.
Why the Name Changed
For decades, this condition was called neurofibromatosis type 2. That name turned out to be misleading. Neurofibromas, the nerve tumors that define neurofibromatosis type 1 (NF1), don’t actually occur in NF2. The tumors in NF2 are schwannomas, which grow from a different type of cell entirely. In 2022, an international consensus formally renamed the condition “NF2-related schwannomatosis” to correct this and to reduce confusion between NF1 and NF2, two very different diseases that were too easily mixed up.
The “NF2-related” part of the new name matters because other genetic conditions also cause multiple schwannomas. Mutations in different genes (called SMARCB1 and LZTR1) produce overlapping symptoms. What sets NF2-related schwannomatosis apart is the specific gene involved and the characteristic pattern of bilateral tumors on the hearing nerves.
The Genetic Cause
NF2 is caused by mutations in a gene on chromosome 22 that produces a protein called merlin. Merlin acts as a brake on cell growth. It tells certain cells when to stop dividing and helps them maintain their normal shape and connections to neighboring cells. When the gene is mutated, the body produces a shortened, nonfunctional version of this protein, and the brake fails.
Without working merlin, Schwann cells are especially vulnerable. These are the cells that wrap around and insulate nerve fibers throughout the body. Freed from normal growth control, they multiply and form tumors called schwannomas. The same loss of merlin can also trigger the growth of other tumor types in the brain and spinal cord, both benign and occasionally cancerous.
NF2 follows an autosomal dominant inheritance pattern, meaning a single copy of the mutated gene from one parent is enough to cause the condition. Each child of an affected parent has a 50% chance of inheriting it. However, a significant number of cases arise from brand-new (de novo) mutations in people with no family history.
Vestibular Schwannomas: The Defining Feature
Almost all people with NF2 develop schwannomas on both hearing and balance nerves by age 30. These tumors, called vestibular schwannomas, grow where the nerve exits the brainstem and enters the inner ear. As they enlarge, they press on the nerve and surrounding structures.
The earliest symptoms are usually gradual hearing loss in one or both ears, persistent ringing (tinnitus), and problems with balance. Because the tumors grow slowly, hearing loss can creep in over months or years before someone notices it. In some cases, sudden hearing loss is the first sign. As tumors grow larger, they can press on nearby nerves and cause facial numbness, weakness, or difficulty swallowing.
Other Tumors in NF2
Vestibular schwannomas get the most attention, but NF2 affects much more than the hearing nerves. Meningiomas, tumors that grow from the membranes surrounding the brain and spinal cord, develop in 48% to 75% of NF2 patients. In children, these tend to appear along the base of the skull. In adults, they more commonly form along the top and midline of the brain. Most are benign and slow-growing, but those near the optic nerves or at the skull base can create serious complications.
Spinal tumors called ependymomas occur in up to 65% of patients. These grow from cells lining the central canal of the spinal cord. Schwannomas can also develop on spinal nerve roots and peripheral nerves throughout the body, sometimes causing localized pain, weakness, or numbness depending on which nerve is affected.
Eye Problems as Early Clues
NF2 can affect the eyes in ways that sometimes appear before any hearing symptoms, making them valuable early warning signs. The most characteristic finding is a juvenile posterior subcapsular cataract, a specific type of clouding at the back of the lens that develops at an unusually young age. These cataracts may be subtle enough that they’re only noticed during a dilated eye exam.
Other eye findings include epiretinal membranes, thin sheets of scar-like tissue that form on the surface of the retina and can distort vision. In one documented case, a child failed an eye screening at age 10 and was found to be effectively blind in one eye from this type of membrane. Schwannomas can even develop within the wall of the eye itself. For families with a known NF2 mutation, pediatric eye exams can help identify affected children early.
How NF2 Is Diagnosed
Diagnosis relies on a combination of clinical findings and, increasingly, genetic testing. The most widely used framework is a revised version of the Manchester criteria, updated in 2019. The clearest path to diagnosis is bilateral vestibular schwannomas on MRI, which is essentially diagnostic on its own. But because not everyone develops bilateral tumors early, the criteria also account for combinations of other findings: a unilateral vestibular schwannoma plus meningiomas, cataracts, ependymomas, or a family history of NF2.
The updated criteria added an age limit of 70 for the development of vestibular schwannomas to be counted toward diagnosis, since sporadic (non-NF2) schwannomas become more common in older adults. Molecular testing for mutations in the NF2 gene has also been formally incorporated, which is particularly useful for confirming mosaic cases where only some cells in the body carry the mutation and symptoms may be milder or more limited.
Treatment Approaches
There is no cure for NF2, and treatment focuses on managing individual tumors to preserve function for as long as possible. The approach depends on tumor size, location, growth rate, and the patient’s current symptoms.
Many tumors are simply monitored with regular MRI scans, especially when they’re small and not causing symptoms. This “watch and wait” strategy avoids the risks of treatment when a tumor isn’t yet threatening function.
Surgery is typically considered for vestibular schwannomas when hearing has already been lost in that ear or when the tumor is small enough that removing it gives a reasonable chance of preserving the hearing nerve. For larger tumors pressing on the brainstem, surgery may be necessary regardless of hearing status. Radiation therapy takes a different approach, aiming to slow or shrink tumors to preserve hearing longer and reduce neurological complications without the risks of open surgery.
A medication that blocks blood vessel growth in tumors has shown some benefit. In a prospective clinical trial, 41% of participants experienced measurable hearing improvement at six months, and 32% saw their tumors shrink on imaging. Notably, these responses were seen almost entirely in adults. Pediatric participants in the same trial did not experience tumor shrinkage, suggesting that NF2 tumors in children may behave differently at a biological level.
Living With NF2
Because NF2 typically appears in adolescence or early adulthood and requires lifelong monitoring, it shapes major life decisions around education, career, and family planning. Regular MRI scans, hearing assessments, and eye exams become part of routine care. Hearing loss is the most common long-term challenge, and many people with NF2 eventually rely on hearing aids, cochlear implants, or auditory brainstem implants depending on which structures remain functional.
Genetic counseling plays an important role for affected families. For someone with NF2 considering having children, testing can clarify whether the mutation was inherited or spontaneous, which directly affects the risk of passing it on. Prenatal and preimplantation genetic testing are available for families with a known mutation. Coordinated care through a specialty NF clinic, where neurologists, surgeons, audiologists, and ophthalmologists work together, generally produces better outcomes than fragmented care across unconnected providers.